SusPharma - Merging Sustainable and Digital Chemical Technologies for the Development of Greener-by-Design Pharmaceuticals

安全和绿色设计是上市前的设计方法，将尽量减少使用危险化学品、减少温室气体排放以及促进循环经济中材料的再利用和回收的目标纳入产品设计。SUSPHARMA符合欧洲对现代工业可持续发展的需求，并将在行动期间开发更绿色的路线来制备分子，如治疗和诊断。突破性创新将涉及：-使用可再生能源- 用于药物合成的支架和基序的构建块的（生物基）碳;- 开发新的台式连续纯化方法，以除去杂质并再循环合成溶剂;- -数字化手段融合。- LCA和TEA评估，以合理降低药品生产的影响。因此，该项目将受益于跨学科领域，涉及：-生物质转化用于药物合成的最新进展; -多相催化的新发展; -尖端流动化学技术（包括合成和纯化）; -自动化和机器学习。为了应对绿色和数字化转型的挑战，以及健康技术和产品的适当供应，SUSPHARMA将专注于研究和创新活动，旨在整合五个突破性概念：CAT到PHARMA，WASTE到PHARMA，FLOW-to-PHARMA，PUR-to-PHARMA和DIGITAL to PHARMA。这将为制药行业、研究人员和创新者带来成果，促使他们开发和生产更环保的药物，这些药物要么设计更环保，对环境的危害更小，要么使用更环保、经济上更可持续的制造工艺和技术。

Safe-and green-by-design are pre-market design approaches whereby the objectives of minimizing the use of hazardous chemicals, reducing greenhouse gas emissions, and fostering the reuse and recycling of materials in a circular economy are built into product design. SUSPHARMA fits the European need for sustainable development in modern industry and will develop during the action greener routes to prepare molecules, such as therapeutics and diagnostics. The breakthrough innovation will involve: - use of renewable (bio-based) carbon for the building block of scaffolds and motifs for drug synthesis; - cleaner synthetic methodologies for C-X bond formation (that is, C-H functionalization to obtain C-C, C-F, and C-I bond formation); - development of new benchtop continuous purification methods, to remove impurity and recycle synthetic solvents; - integration of digitalization methods. - LCA and TEA assessment for sensibly reducing the impact of pharmaceutical production. The project will thus benefit from an interdisciplinary domain, involving: - recent advances in biomass conversion for drug synthesis; - new developments in heterogeneous catalysis; - cutting-edge flow chemistry technologies (including synthesis and purification); - automation and machine learning. To address the challenge of green and digital transition and proper supply of health technologies and products, SUSPHARMA will focus on research and innovation activities that aim at integrating five breakthrough concepts: CAT-to-PHARMA, WASTE-to-PHARMA, FLOW-to-PHARMA, PUR-to-PHARMA, and DIGITAL to PHARMA. This will deliver results that are directed to pharmaceutical industries, researchers, and innovators, prompting them to develop and produce greener pharmaceuticals that are either greener by design, intrinsically less harmful for the environment, or use greener and economically more sustainable manufacturing processes and technologies.